We are on a mission tooutsmart cancer resistance.
Theseus is developing next-generation kinase inhibitors to transform the way cancer is treated.
Our investigational oncology therapies are designed to address treatment-resistant cancer mutations.
Working to deliver best-in-class pan-variant Tyrosine Kinase Inhibitors (TKIs) to cancer patients.
We are developing a pipeline of TKIs designed to inhibit all major cancer causing and drug resistance mutations in clinically significant protein kinases.
View our latest news.
Dec 16, 2021
We are building a community working to outsmart cancer resistance. Join us!
SEE OPEN ROLES